Skip to main content
Clinical Trials/NL-OMON29781
NL-OMON29781
Recruiting
Phase 2

Influence on brain perfusion and metabolism through pharmacologic agents - perfusie_pharma

niversitair Medisch Centrum Groningen0 sites30 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
multiple sclerosis
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
30
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) a diagnosis of MS, according to the McDonald criteria with a secondary progressive disease course and a disease duration of between ten and fifteen years
  • 2\) age 18\-60 years
  • 3\) informed consent

Exclusion Criteria

  • 1\) use of systemic corticosteroids in the eight weeks before inclusion into the trial
  • 2\) use of immunomodulatory treatments for MS
  • 3\) a history of cerebral pathology other than MS (cerebral infarct, cerebral haemorrhage, Parkinson's disease, Alzheimer's disease, cerebral vasculitis, brain absces)
  • 4\) diabetes mellitus, cardiac arrhytmia, prolonged qt time on ecg, pregnancy or breast feeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials